Abstract
Among neutral endopeptidase (NEP) inhibitors, mercaptoacyldipeptides implicated in cardiovascular diseases, are of great interest. Two groups, Coric et al. and Oefner et al. described two different binding preferences for mercaptoacyldipeptides at the active site of NEP. By focusing on both, 3D-QSAR studies were performed on mercaptoacyldipeptides, based on conformational alignment obtained by GOLD 3.2, using CoMFA and CoMSIA techniques. Statistically significant 3D-QSAR models were obtained with q2 of 0.580 and 0.559, and r2 of 0.996 and 0.991, respectively. Both the models were validated by an external test set of nine compounds giving highly predictive r2 (pred) of 0.929 and 0.928, respectively. The study will facilitate the rational design of more potent mercaptoacyldipeptides for the treatment of cardiovascular diseases.
Keywords: Comparative molecular field analysis, comparative molecular similarity analysis, mercaptoacyldipeptides, neutral endopeptidase
Medicinal Chemistry
Title: Receptor-Based 3D-QSAR Study for Recognizing True Binding Mode of Mercaptoacyldipeptides at the Active Site of Neutral Endopeptidase
Volume: 5 Issue: 1
Author(s): Zaheer-ul-Haq and Sadaf Iqbal
Affiliation:
Keywords: Comparative molecular field analysis, comparative molecular similarity analysis, mercaptoacyldipeptides, neutral endopeptidase
Abstract: Among neutral endopeptidase (NEP) inhibitors, mercaptoacyldipeptides implicated in cardiovascular diseases, are of great interest. Two groups, Coric et al. and Oefner et al. described two different binding preferences for mercaptoacyldipeptides at the active site of NEP. By focusing on both, 3D-QSAR studies were performed on mercaptoacyldipeptides, based on conformational alignment obtained by GOLD 3.2, using CoMFA and CoMSIA techniques. Statistically significant 3D-QSAR models were obtained with q2 of 0.580 and 0.559, and r2 of 0.996 and 0.991, respectively. Both the models were validated by an external test set of nine compounds giving highly predictive r2 (pred) of 0.929 and 0.928, respectively. The study will facilitate the rational design of more potent mercaptoacyldipeptides for the treatment of cardiovascular diseases.
Export Options
About this article
Cite this article as:
Zaheer-ul-Haq and Iqbal Sadaf, Receptor-Based 3D-QSAR Study for Recognizing True Binding Mode of Mercaptoacyldipeptides at the Active Site of Neutral Endopeptidase, Medicinal Chemistry 2009; 5 (1) . https://dx.doi.org/10.2174/157340609787049253
DOI https://dx.doi.org/10.2174/157340609787049253 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Polyunsaturated Fatty Acids and Cardiovascular Disease
Current Pharmaceutical Design Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine
Current Medicinal Chemistry Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension
Current Hypertension Reviews Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Current Alzheimer Research Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets MicroRNA Therapeutics for Cardiac Regeneration
Mini-Reviews in Medicinal Chemistry